Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
Hepion Pharmaceuticals (NASDAQ:HEPA) has received a delisting notification from Nasdaq on May 9, 2025. The company's stock will be suspended from trading on Nasdaq effective May 13, 2025, and is expected to transition to trading on the OTC Markets Group under the symbol "HEPA". The delisting is due to two main compliance failures: not maintaining a minimum bid price of $1.00 per share (Rule 5550(a)(2)) and Nasdaq's determination that the company is a public shell (Rule 5101).
Notably, Hepion has undergone a significant business transformation from a clinical stage biopharmaceutical company developing NASH, HCC, and liver disease treatments to becoming a developer and distributor of diagnostic tests for celiac disease, respiratory multiplex, H. pylori, and HCC.
Hepion Pharmaceuticals (NASDAQ:HEPA) ha ricevuto una notifica di esclusione da Nasdaq il 9 maggio 2025. Le azioni della società saranno sospese dalla negoziazione su Nasdaq a partire dal 13 maggio 2025 e si prevede che saranno quotate sul mercato OTC Markets Group con il simbolo "HEPA". L'esclusione è dovuta a due principali violazioni di conformità: non aver mantenuto un prezzo minimo di offerta di 1,00 dollaro per azione (Regola 5550(a)(2)) e la determinazione di Nasdaq che la società è una shell pubblica (Regola 5101).
È importante sottolineare che Hepion ha subito una trasformazione significativa, passando da una società biofarmaceutica in fase clinica che sviluppava trattamenti per NASH, HCC e malattie epatiche, a un'azienda che sviluppa e distribuisce test diagnostici per la celiachia, multiplex respiratorio, H. pylori e HCC.
Hepion Pharmaceuticals (NASDAQ:HEPA) recibió una notificación de exclusión de Nasdaq el 9 de mayo de 2025. Las acciones de la compañía serán suspendidas de negociación en Nasdaq a partir del 13 de mayo de 2025 y se espera que pasen a cotizar en el mercado OTC Markets Group bajo el símbolo "HEPA". La exclusión se debe a dos incumplimientos principales: no mantener un precio mínimo de oferta de $1.00 por acción (Regla 5550(a)(2)) y la determinación de Nasdaq de que la compañía es una shell pública (Regla 5101).
Es importante destacar que Hepion ha experimentado una transformación significativa, pasando de ser una empresa biofarmacéutica en etapa clínica que desarrollaba tratamientos para NASH, HCC y enfermedades hepáticas, a convertirse en un desarrollador y distribuidor de pruebas diagnósticas para la enfermedad celíaca, multiplex respiratorio, H. pylori y HCC.
Hepion Pharmaceuticals (NASDAQ:HEPA)는 2025년 5월 9일 나스닥으로부터 상장폐지 통보를 받았습니다. 회사의 주식은 2025년 5월 13일부터 나스닥 거래가 정지되며, "HEPA"라는 심볼로 OTC Markets Group에서 거래될 예정입니다. 상장폐지는 두 가지 주요 규정 위반 때문입니다: 주당 최소 입찰가 $1.00 미달 (규칙 5550(a)(2))과 회사가 공개 쉘(public shell)로 판단된 점(규칙 5101)입니다.
특히, Hepion은 NASH, HCC 및 간 질환 치료제를 개발하는 임상 단계의 바이오제약 회사에서 셀리악병, 호흡기 다중진단, H. pylori 및 HCC 진단 테스트를 개발 및 유통하는 회사로 사업 구조를 크게 전환하였습니다.
Hepion Pharmaceuticals (NASDAQ:HEPA) a reçu une notification de radiation de la part de Nasdaq le 9 mai 2025. Les actions de la société seront suspendues de la négociation sur Nasdaq à compter du 13 mai 2025 et devraient être transférées sur le marché OTC Markets Group sous le symbole "HEPA". Cette radiation est due à deux manquements majeurs aux règles : ne pas avoir maintenu un prix d'offre minimum de 1,00 $ par action (Règle 5550(a)(2)) et la détermination par Nasdaq que la société est une société coquille publique (Règle 5101).
Il est à noter qu'Hepion a subi une transformation importante, passant d'une société biopharmaceutique en phase clinique développant des traitements pour la NASH, le CHC et les maladies du foie à un développeur et distributeur de tests diagnostiques pour la maladie cœliaque, les multiplex respiratoires, H. pylori et le CHC.
Hepion Pharmaceuticals (NASDAQ:HEPA) erhielt am 9. Mai 2025 eine Delisting-Mitteilung von der Nasdaq. Die Aktien des Unternehmens werden ab dem 13. Mai 2025 vom Handel an der Nasdaq ausgesetzt und sollen unter dem Symbol "HEPA" auf dem OTC Markets Group gehandelt werden. Das Delisting erfolgt aufgrund von zwei wesentlichen Verstößen gegen Compliance-Anforderungen: Unterschreitung des Mindestgebotspreises von 1,00 USD pro Aktie (Regel 5550(a)(2)) und die Feststellung der Nasdaq, dass das Unternehmen eine öffentliche Shell-Gesellschaft ist (Regel 5101).
Bemerkenswert ist, dass Hepion eine bedeutende geschäftliche Transformation durchlaufen hat, von einem biopharmazeutischen Unternehmen in der klinischen Phase, das Behandlungen für NASH, HCC und Lebererkrankungen entwickelt, hin zu einem Entwickler und Vertreiber von Diagnosetests für Zöliakie, respiratorische Multiplex-, H. pylori- und HCC-Tests.
- Transition to diagnostic test business model may provide new revenue opportunities
- Company maintains trading capability through OTC Markets
- Delisting from Nasdaq, indicating serious compliance issues
- Stock price below $1.00, showing significant market value deterioration
- Company classified as a 'public shell' by Nasdaq
- Abandonment of original NASH and liver disease treatment pipeline
- Potential reduced access to capital and decreased stock liquidity after moving to OTC
MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases which has transitioned to a developer and distributor of diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), H. pylori and HCC, today announced that on May 9, 2025, the Company received written notice (the “Notice”) from the Office of General Counsel of The Nasdaq Stock Market (“Nasdaq”) indicating that the Nasdaq Hearings Panel has determined to delist the Company’s shares from Nasdaq due to the Company’s failure to meet Nasdaq’s continued listing standards. As previously disclosed, the Company has not been compliant with the requirements under Nasdaq Listing Rule 5550(a)(2) to maintain a minimum bid price of
Upon suspension of the trading of its Common Stock on Nasdaq, the Company expects that its Common Stock will be quoted under its existing symbol “HEPA” on the OTC Markets Group.
About Hepion Pharmaceuticals
Hepion’s primary asset, Rencofilstat, is a potent inhibitor of cyclophilins, which are involved in many disease processes. Rencofilstat has been shown to reduce liver fibrosis and hepatocellular carcinoma tumor burden in experimental disease models.
In April 2024, Hepion announced that it was winding down its ASCEND-NASH clinical trial. This trial was designed as a Phase 2b, randomized, multi-center, double-blinded study with first patient screened in August 2022, to evaluate the safety and efficacy of Rencofilstat dosed for 12 months, with a target enrollment of 336 subjects. Enrollment was paused in April 2023, with 151 subjects randomized. To date, approximately 80 subjects have completed their Day 365 visits and are evaluable for both safety and efficacy.
On May 9, 2025, Hepion entered into a license agreement with New Day Diagnostics LLC to in-license diagnostic tests for celiac disease, respiratory multiplex (Covid/Influenza A/B and RSV), helicobacter pylori (H. pylori) and hepatocellular carcinoma (HCC). The celiac, respiratory multiplex and H. pylori tests have CE marks and are eligible to be sold in Europe at the present time.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated,” and “intend,” among others. These forward-looking statements are based on Hepion Pharmaceuticals’ current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; risks associated with delays; uncertainties with respect to lengthy and expensive clinical trials, that results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. Hepion Pharmaceuticals does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Hepion Pharmaceuticals’ Form 10-K for the year ended December 31, 2024, and other periodic reports filed with the Securities and Exchange Commission.
For further information, please contact:
Hepion Pharmaceuticals
info@hepionpharma.com
FAQ
Why is HEPA stock being delisted from Nasdaq?
When will Hepion Pharmaceuticals (HEPA) stop trading on Nasdaq?
Where will HEPA stock trade after Nasdaq delisting?
What is Hepion Pharmaceuticals' new business focus?
What are the implications of HEPA moving to OTC Markets?
